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Transfer of genetic material into recipient cells by trans-
fection has been used successfully to isolate genes respons-
ible for particular phenotypic traits. By using this strategy,
DNA fragments were isolated that when transfected into
appropriate uncommitted cells will commit the recipient
cells to undergo adipocyte differentiation. Transgenic
mice were generated with one of the active DNA clones,
Clone B. The transgenic mice were expected to display
an adipocyte-related phenotype; however, the animals
developed melanin containing tumors at a young age.
Insertion of Clone B into the mouse DNA probably
interrupted a gene(s) that is involved in the regulation of
cell growth, specifically regulation of cell growth in
melanin-producing cells. Histopathologic analysis of
Melanoma is the result of the neoplastic transformationof melanocytes of the skin or other tissues. Theincidence and mortality rate of melanoma haveincreased dramatically among Caucasians during thelast decade. By the end of this century, approxi-
mately one in 100 Caucasians in the United States will develop
melanoma in their lifetime. Multiple etiologic factors lead to the
development of melanoma. One set of the factors is genetic, whereas
other factors include several carcinogenic stimuli applied to that genetic
predisposition.
Several oncogenes and tumor suppressor genes have been implicated
in the progression of melanoma. Cytogenetic analysis of primary
melanomas often shows loss of heterozygosity of specific regions of
several chromosomes, strongly suggesting the presence of tumor
suppressor genes (Becher et al, 1983; Balaban et al, 1984; Trent, 1991;
Thompson et al, 1995). One such putative tumor suppressor gene,
Multiple Tumor Suppressor 1 (MTS1), located on chromosome 9p21,
is frequently rearranged or deleted in familial melanoma (Hussussian
et al, 1994; Kamb et al, 1994; Wolfel et al, 1995). MTS1 has been
shown to encode a previously identified protein, p16, which is known
to bind to and inhibit the activity of cyclin-dependent-kinase 4 (cdk4)
during the cell cycle (Hussussian et al, 1994; Kamb et al, 1994; Wolfel
et al, 1995). Analysis of p16 protein in over 100 melanomas showed
that a large number of the tumors examined retained expression of
p16 (Wick et al, 1995); however, these melanoma-associated p16
proteins are mutated and are thus defective in cdk4 binding. These
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these mice showed dark spots on the ear lobes of the
animals as early as 10–12 d of age. By 3 mo, in addition
to the ear lobes, pigmented tumors could be observed in
other organs. A significant number of these transgenic
mice died within 1 y of age. The melanomas developed
spontaneously in these animals in the absence of any
known chemical carcinogen or ultraviolet radiation. This
line of mice provides a way of identifying genes involved
in regulation of cell growth control and differentiation.
These mice also serve as a model system to investigate
the molecular, genetic, and phenotypic characterization
and development of melanomas. Key words: insertion
mutagenesis/melanocytes/spontaneous skin lesions. J Invest
Dermatol 110:247–252, 1998
results suggest that p16 mutation, via its deregulation of the cdk4
pathway, is of biologic significance in the development of melanoma
(Wick et al, 1995). In addition to chromosome 9, chromosomes 1, 3,
6, 7, and 11 have been shown to be altered in malignant melanomas
(Healy et al, 1995). The long arm of chromosome 6 shows preferential
loss of heterozygosity through deletion or rearrangement in a large
number of cases of human malignant melanoma. The re-introduction
of a normal human chromosome 6 into human melanoma cells results
in the loss of the malignant phenotype (Trent et al, 1990; Church et al,
1993; Zhang et al, 1995; Ray et al, 1996), suggesting the presence of
a ‘‘melanoma suppressor gene’’ within this region of chromosome 6.
At least two putative ‘‘tumor suppressor genes’’ on the long arm of
chromosome 6 have been identified (Church et al, 1993; Ray et al,
1997). Taken together, it is clear that melanoma is a complex disease
whose etiology may involve several possible pathways controlling
normal melanocytic functions. Data describing the proto-oncogenes
and tumor suppressor genes suggest that mutations in any of the genes
controlling growth and/or differentiation of cells may lead to neoplastic
transformation (Trent, 1991). Other as yet unidentified genes, such as
those involved in the control of proliferation and differentiation of
pigment cells, if altered, would be candidates for transforming genes.
To date, the animal model system best characterized for the develop-
ment of melanoma at the molecular level is the hybrid between the
Mexican platyfish (Platypoecilus maculatus) and the swordtail (Xiphophorus
hellerii). The hybrid fish develop benign and malignant melanocytic
lesions. A ‘‘genetic imbalance’’ in the black spotted members of the
hybrid fish is associated with an atypical growth of melanocytes
(Schwab, 1987; Wittbrodt et al, 1989; Anders, 1991). Selective breeding
of the fish abolished a tumor suppressor gene, thus deregulating an
oncogene and inducing melanoma (Schwab, 1987; Wittbrodt et al,
1989). The putative oncogene (Xmrk) was cloned and shown to be
homologous to human epidermal growth factor receptor (Schwab,
1987; Wittbrodt et al, 1989).
Currently, very few experimental animal models exist for melanoma
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formation and most murine models require a combination of carcinogen
and ultraviolet radiation treatments (Bickers and Low, 1989; Romerdahl
et al, 1989; Yuspa and Dlugosz, 1991). The majority of neoplasias
resulting from these treatments are papillomas, squamous cell carcin-
omas, and fibrosarcomas; the development of melanoma is very
infrequent (Bickers and Low, 1989; Romerdahl et al, 1989; Yuspa and
Dlugosz, 1991). There have been several transgenic mouse models for
development of melanocytic tumors (Bradl et al, 1991; Iwamoto et al,
1991; Larue et al, 1992; Taniguchi et al, 1992; Mintz et al, 1993). One
transgenic mouse model for melanoma carried the early region of
SV40 regulated by the tyrosinase promoter (Bradl et al, 1991; Larue
et al, 1992; Mintz et al, 1993). Another transgenic mouse model carried
the ret oncogene under the regulation of metallothionein promoter-
enhancer (Iwamoto et al, 1991; Taniguchi et al, 1992). Ocular tumors
developed in both types of transgenics (Bradl et al, 1991; Iwamoto
et al, 1991; Larue et al, 1992; Taniguchi et al, 1992; Mintz et al, 1993)
and melanocytic tumors arose frequently in the dermis of ret-transgenics
(Iwamoto et al, 1991; Taniguchi et al, 1992). In both studies the
transgenic mice were constructed with a known oncogene.
We have established five independent transgenic mouse lines with
the insertion of a piece of genomic DNA, Clone B (Teicher et al,
1993). Transfection of Clone B DNA into several cells results in the
differentiation of the cells to adipocytes (Teicher et al, 1993). Of these
five independent transgenic lines, one spontaneously develops heritable
melanoma. We hypothesize that the site of the host gene where the
transgene is inserted must play an important role in the development
of the tumor. The interruption of host sequences by the inserted
transgene may have activated an ‘‘off’’ oncogene to the ‘‘on’’ state,
thus modulating its expression and resulting in the transformation of
cells. Alternatively, our transgene may have interrupted a tumor
suppressor gene, leading to unregulated expansion of targeted cells. A
third possibility is that specific interaction(s) occur between our
transgene and the interrupted host sequences; such interaction(s)
resulted in tumor development.
Earlier we reported a preliminary description of the development
of melanotic lesions in one of the lines of the transgenic mice described
above (Chen et al, 1996). This paper describes in detail the distribution,
histology, and clinical progression of the melanotic lesions in these
transgenic mice. These lesions resemble human cuboid (P. Durray,
National Cancer Institute, Bethesda, MD, personal communication)
cell melanoma and are detected in skin, eyes, lymph nodes, lung, inner
ear, brain, and muscle.
MATERIALS AND METHODS
Generation of transgenic mouse lines The founder transgenic mice were
generated by insertion of Clone B DNA in C57BL/6 J 3 SJL F1 hybrid mice
(DNX, Princeton, NJ). Initially, the transgenic lines were maintained by back
crossing to C57BL/6 J. After six generations, the transgenic mice were
maintained by brother–sister mating. All animals were maintained in a germ-
free environment and provided food and water ad libitum. Transgenic mice
were identified by Southern hybridization to Clone B DNA with genomic
DNA prepared from tail biopsies (Chen et al, 1996).
Histologic analysis Animals were inspected for tumor development twice
weekly. Mice were sacrificed with CO2 according to the Rutgers University
policy on animal welfare. Complete autopsies were performed on all animals,
and tissue samples were fixed in 10% neutral buffered formalin. Skull, including
eye and bone, were decalcified for 3 d in phosphate-buffered saline with 10%
formaldehyde and 5% formic acid. Standard procedures were followed for
paraffin embedding, sectioning and hematoxylin and eosin staining as described
(Luna, 1992).
For bleaching of the melanin in the tissues, 6 µm sections were deparaffinized
and hydrated with distilled water. Samples were then bleached overnight in a
solution containing 20 ml benzyl alcohol, 10 ml acetone, 5 ml 10% hydrogen
peroxide, and four drops of 25% ammonia solution at 37°C. The samples were
subsequently immersed in acetone:distilled water (1:1) for 5 min, rinsed in
distilled water for 5 min, treated in 20% N2S2O3 for 30 min, rinsed again in
distilled water for 5 min, and dried at 37°C for 30 min. The bleached slides
were then stained with hematoxylin and eosin.
Electron microscopy Tumor samples for electron microscopy were trimmed
into 1 mm3 cubes and fixed in 2.5% phosphate-buffered glutaraldehyde for
Table I. Affected organs in transgenic mice
Number of animals affected/total (%)
Organs examined Stage 1 Stage 2 Stage 3 Stage 4
for lesions
Skin:pinnae of 15/15 (100) 25/25 (100) 63/63 (100) 106/106 (100)
the ear
Skin:perianal 13/15 (87) 25/25 (100) 63/63 (100) 106/106 (100)
region
Skin:other areas 4/15 (27) 22/25 (88) 63/63 (100) 106/106 (100)
Eye 5/15 (33) 25/25 (100) 63/63 (100) 106/106 (100)
Skull 0/15 (0) 2/25 (8) 26/63 (41) 78/106 (74)
Lymph node 9/15 (60) 24/25 (96) 63/63 (100) 106/106 (100)
Lung 0/15 (0) 1/25 (4) 12/63 (19) 65/106 (61)
Brain 0/15 (0) 0/25 (0) 7/63 (11) 14/106 (13)
Muscle 0/15 (0) 0/25 (0) 9/63 (14) 58/106 (55)
Spleen 0/15 (0) 1/25 (4) 19/63 (30) 79/106 (75)
Liver 0/15 (0) 0/25 (0) 17/63 (27) 92/106 (87)
12 h. Following postfixation in osmium tetroxide for 90 min, samples were
dehydrated and embedded in Epon-Araldite by standard procedures (Hayat,
1989). Thin sections (60 nm) were prepared, stained, and examined on a Zeiss
10CA electron microscope.
RESULTS
Generation of transgenic lines In all five independent lines of
transgenic founder mice (TG1–5) bearing insertion of the Clone B
DNA, the transgene was found to be in head-to-head, head-to-tail,
or tail-to-tail arrangements. There were 5–7 copies of the transgene
inserted in each line. In one of the five transgenic lines, TG-3, the
founder mother developed pigmented lesions at about 8 mo and was
killed at 14 mo of age. Mice from the TG-3 transgenic line were
backcrossed to C57BL/6 J for the first six generations, then maintained
by brother–sister mating. This paper describes studies done with mice
derived from the TG-3 line.
In this study a total of 519 mice (282 males and 237 females) were
examined for their phenotypic appearance. Tissue samples from some
animals were further analyzed by histopathologic means. There were
84 nontransgenic mice (52 males and 32 females) and the remainder
of the animals were transgenic and were divided into four cohorts
based on the age of the animals when the appearance of the external
lesions was detected. The first cohort had 70 animals (33 males and
37 females). These mice developed externally visible pigmented lesions
in perianal region, pinnae of the ear, eyes, snout, legs, tail, and other
parts of the skin within 2–4 wk of birth. The lesions rapidly increased
in size (to 0.5–1.5 cm) and most of the mice died between 2 and 5 mo
of age. The second cohort had 257 animals (144 males and 113
females). These animals showed an anatomical distribution of lesions
similar to that described in the first cohort, but exhibited a delay of
the development of the lesions until 5–7 mo of age. Animals in this
cohort died by 6–8 mo of age. The third cohort had 43 animals (15
males and 28 females). Animals in this cohort showed the pigmented
lesions at about 8 mo of age, a time-course similar to the founder
mother, and all died by 14 mo of age. The fourth cohort had 65
animals (38 males and 27 females). These animals did not manifest
pigmented lesions at any point during their lifetime. The life span of
these mice was similar to that of the nontransgenic mice.
Because the animals in the first cohort became sick and either died
or were killed while relatively young, it was difficult to obtain progeny
from them. Subsequently all animals are derived by crosses of the
animals within the second and third cohorts. To assess the progression
of the lesions, histologic examinations were carried out on mice
randomly chosen from cohorts one, two, or three. A rating system of
four stages was used for the histologic analysis, based on morphology,
size of the tumor, and site of the lesions, with stage 1 being the least
and stage 4 being the most extensively involved, as defined by the
number of organs affected and the severity in the appearance of the
lesions (Table I). A transgenic mouse manifesting typical stage 3 and
stage 4 lesions is shown in Fig 1(A, B, respectively).
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Figure 1. Transgenic mice. (A) Tumors on the perianal region of a 1-y-old
transgenic mouse at stage 4. (B) Tumors on the ear, eye, and snout of an 8-
mo old transgenic mouse at stage 3.
Gross morphologic evaluation of transgenic and control
mice Control, nontransgenic mice (10 animals) were included in
this evaluation and no lesions were detected in any organ. A total of
209 animals from the first, second, and third cohorts were analyzed
histopathologically. Mice of similar ages from each cohort were analyzed
and compared. Regardless of the cohort, the lesions were always first
detected grossly on the skin of the ear and the perianal region, and
then other parts of the body including the snout, the tail, the back,
the eyes, and the legs. The results of necropsies of affected mice at
different stages and the number of organs affected grossly are shown
in Table I.
Gross pathology of transgenic mice Stage 1 Animals began to
show pigmented spots on the ear and perianal region, but the lesions
did not appear as raised spots on the skin. The Harderian glands were
darker and slightly larger than those of normal mice. The lymph nodes
were black or enlarged in nine mice (60% of animals in stage 1). No
other organs were found to be affected. A total of 15 mice were
assigned to stage 1.
Stage 2 Raised pigmented lesions were seen on the ears and perianal
region. The thickness of the lesions was about 1 mm on the ears and
1–3 mm at the perianal region. Additional lesions appear on the snout,
eyelid, and back of the animals. The Harderian glands of the eye were
about twice the normal size and were completely black. Exophthalmia
was not apparent. Stage 2 mice generally presented initial lymph node
involvement in the aortic, axillary, ilioinguinal, and cervical nodes
(96% of affected animals in stage 2). A small number of animals showed
pigmented lesions in skull, lung, and spleen. A total of 25 mice were
assigned to stage 2.
Stage 3 The thickness of the pigmented lesions on the ears was 1–
3 mm and 3–8 mm at the perianal region. The lesions on the snout
and eyelid were raised and enlarged. Additional pigmented spots were
detected on other parts of the skin. Eyes were exophthalmic due to
the progressive enlargement of the Harderian glands and increased
thickness of the choroid. These affected mice were not as active as
control nontransgenic mice of the same age. Virtually all lymph nodes
were affected. Of 63 animals assigned to stage 3, 19% had lesions
within the lung, 41% had lesions of the skull, 11% had lesions of the
brain, 14% had lesions of muscle, and 30% had lesions of spleen; in
27% of animals, livers were markedly discolored, appearing gray-black.
Stage 4 The size and thickness of the pigmented lesions on the ears,
the eyelid, the snout, and the perianal region were even larger and
thicker than those in stage 3. Ulceration was seen in some of the
lesions. The lesions on other parts of the skin continued to increase in
number and many of them were raised. Bilateral exophthalmia was
more prominent. Tumor involvement of the Harderian glands, if
allowed to progress, would likely have occupied the entire orbital
fossa. When mice reached this stage, they usually died within 2 wk or
were killed for humane reasons. There were 106 mice assigned to
this cohort.
Histopathology Skin All affected transgenic mice had pigmented
lesions on their skin. The number and the size of the lesions increased
as the condition of the animal worsened. Histologically, multifocal
pigmented tumor nests or nodules were detected in the dermis of skin
in all affected mice. Small tumor nests were surrounded by compressed
connective tissue. The tumors contained a mixture of melanin-
containing, spindle-shaped, or oval-shaped cells grouped in irregular
bundles with interspersed fibroblasts and connective tissue (Fig 2A).
Large tumors showed invasion of adjacent adipose tissue and skeletal
muscle. The cells in large tumors were mainly round and extraordinarily
heavily pigmented. The melanin pigment frequently obscured the
nuclear profile and other cytoplasmic features, which became discernible
only after bleaching (Fig 2B). Epidermis and hair follicles were intact
except in regions of ulceration. Infiltration of inflammatory cells into
the tumors was uncommon.
Lymph node In some of the animals in stage 1, the lymph nodes
appeared to be normal during gross dissection; however, by light
microscopy pigmented tumor cells were seen scattered throughout the
lymph nodes. Generally the cervical, thoracic, abdominal, and inguinal
nodes were pigmented and enlarged. Lymph node involvement pro-
gressed with time (Fig 2C), increasing from 2 mm in diameter in stage
1 to 4–10 mm in diameter in stage 4.
Muscle Single pigmented tumor cells were observed infiltrating between
skeletal muscle fibers in mice of stage 2. Mice in stages 3 and 4
possessed pigmented tumor nests or nodules in the interstitial space
between skeletal muscle fibers, but did not appear to invade the
individual fibers (Fig 2D).
Spleen No tumor cells were found in the spleen either grossly or
microscopically when the mice were in stage 1. With the mice in stage
2, the spleens looked normal grossly but light microscopy revealed
many round, heavily pigmented cells scattered within the parenchyma.
With the mice in stages 3 and 4, the color of the spleen was frequently
gray or black and significantly enlarged. In these spleens, the tumor
cells formed nests or nodules.
Liver In the livers of stage 2 animals, melanin pigmentation was
observed in Kupffer cells, but not hepatocytes. In stage 3 and stage 4
mice, some of the livers were gray or black. Microscopically, an
increase of pigmented Kupffer cells was seen in the liver sinusoids.
The changes in the color of the livers appeared to reflect the
phagocytosis of melanosomes or melanotic debris originally present in
other cells.
Lung Small groups of pigmented cells in the lung were first detected
in stage 2 animals. With animals in stages 3 and 4, the lesions in
the lung appeared as multifocal pigmented nodules. These nodules,
measuring µ1 mm in diameter, were frequently bilateral and located
peripheral in the lung parenchyma. These nodules compressed the
adjacent pulminary parenchyma (Fig 3A), and were comprised of
large, oval tumor cells.
Brain Heavily pigmented tumor masses were first detected in the brain
of the mice in stage 3. Grossly, the pigmented lesions appeared to be
located only in the midline brain structures, particularly the choroid
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Figure 2. Histopathologic evaluation of transgenic mice. (A) Light micrograph of 5 µm sections of tumor from the perianal region from a 6 mo old mouse
at stage 3. Accumulation of large, densely pigmented cells was observed within the dermis but sparing the epidermis. (B) Treatment of specimen from (A) following
chemical bleaching of melanin. Nuclear detail is now visible, revealing large oval nuclei with prominent nucleoli. Mitotic figures were infrequent. (C) Cervical
lymph node of a 5 mo old stage 3 mouse. Densely pigmented tumor cells formed nests, most evident at the periphery of the node. (D) Skeletal muscle from a
stage 2 mouse at 7 mo of age. Infiltration of tumor cells between the muscle fibers is apparent. Scale bar, 100 µm (hematoxylin and eosin).
plexus. These lesions were composed of cells morphologically similar
to those in the skin, eye, and lung (Fig 3B).
Eye The majority of the mice showed pigmented ocular lesions. Upon
dissection, thickening of the choroid and enlargement and darkening
of the Harderian glands were observed bilaterally. As the condition of
the animals progressed, the choroid and the Harderian glands became
larger. Microscopically, the choroid of the eye and the interstitial space
of the Harderian glands were extensively involved by tumor infiltrate
(Fig 3C, D). For the animals in stages 3 and 4, the tumors in the
Harderian glands compressed the glandular tissues. Pigmented cells
appeared to invade the optical tissues and optic nerve in these animals.
The cells of the retinal pigmented epithelium were intact in all animals.
Inner ear Visible pigmented lesions at the base of the skull were first
detected in occasional stage 2 animals. Microscopically, an increased
number of round pigmented cells were present on the vestibular
membrane of the inner ears of stage 1 and stage 2 animals. These
pigmented cells appeared to involve the marrow cavity of the cranial
bone near the inner ear in stage 3 and stage 4 mice. These pigmented
lesions presumably originated from the pigmented cells of the stria vas-
cularis.
Other tissues There was no evidence of involvement of the salivary
gland, thymus, thyroid, testis/ovary, kidney, adrenal gland, gastrointesti-
nal tract, or cardiac muscle in any of the mice examined. Blood smears
of all the animals examined appeared to be unremarkable.
Electron microscopy Electron microscopy of pigmented lesions
from skin, muscle, lymph node, and Harderian gland showed similar
findings (Fig 4). In all lesions, tumor cells became engorged with large
numbers of dense, membrane-bound melanotic bodies that in stage 3
and stage 4 animals obscured or displaced other organelles. The
melanosomes were 0.2–0.8 µM in greatest aspect and were usually
uniformly dense. Occasionally, immature melanosomes containing a
folded or filamentous interior were identified. In liver, melanosomes
were most common within Kupffer cells. In these macrophages,
the melanosomes were usually present within secondary lysosomes,
suggesting that they were phagocytosed debris from other cells.
DISCUSSION
We have developed a line of transgenic mice (TG-3) displaying a
strong genetic predisposition to develop melanoma, whereas the
nontransgenic littermates remain disease free. Results from these
studies strongly suggest cosegregation of the susceptibility to melanoma
development and the presence of the transgene, Clone B. In young
TG-3 animals, the pigmented lesions were first detected on the
skin, where they appeared as multifocal lesions resembling dysplastic
melanocytic nevi. These lesions were progressive, increasing in size
and invading nearby tissues, and histologically resembled human
cuboidal cell melanoma (P. Durray, personal communication).
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Figure 3. Histopathologic evaluation of transgenic mice. (A) A metastatic pigmented tumor in the lung of a 4 mo old mouse at stage 3. (B) Heavily
pigmented cellular aggregation in the interstitial space of the choroid plexus of the brain from a 6 mo old mouse at stage 3. The overlying choroid epithelium is
not involved. (C) and (D) Ocular lesions in a 7 mo old mouse at stage 1. (C) Pigmented cells have proliferated in the interstitial space of the Harderian gland. (D)
Hypercellularity of heavily pigmented round cells in the choroid layer of the eye. Retinal epithelium remained intact. Scale bars, 100 µm (hematoxylin and eosin).
With additional time more organs became involved, either as sites
of metastasis and/or as additional sites of primary tumor
development.
In the mouse the skin melanocytes are located primarily in the
dermis except for the melanocytes of the hair follicles. The pigmented
lesions in the skin of TG-3 transgenic mice originated within the
dermis. In humans, the skin melanocytes reside mainly in the basal
layer of the epidermis. In human cutaneous melanoma, the tumors
always originate in the basal layer of epidermis. Histologic analysis of
early pigmented lesions detected in the skin, the Harderian gland, and
the choroid of TG-3 mice suggested they were of neural crest-derived
melanocytes. All skin lesions appear to derive from melanocytes in the
dermis and none from melanocytes of the hair follicles. Perhaps the
microenvironment surrounding the hair follicle melanocytes precluded
them from becoming tumors. We never detected lesions in retinal
pigment epithelium that is derived from local neuroectoderm.
The transgenic mice in this study were divided into four cohorts
based on the age of the animals when the external pigmented lesions
were first detected. A direct correlation was found between the life
span of the animals and the age at the appearance of the first lesions.
Mice in the first cohort showing the external lesions very early had a
very short life span, whereas those in the fourth cohort never developed
lesions and had life spans similar to those of control nontransgenics.
By Southern blots using our transgene as a probe, no differences were
detected among the four cohorts. Presumably the genetic element that
is critical in the development of the pigmented lesions is inactivated
or lost in cohort four, and we do not yet have the appropriate probe
to identify this element.
The histologic rating of the affected mice was based on the size
of the tumors and the number of organs involved. Tissue samples
from mice in the first cohort were always assigned to stage 3 or
4, because of the severity of their lesions at a young age. Lesions
from younger animals in the second or third cohort were assigned
to stage 1 or 2. With time, mice in these two cohorts developed
more lesions, and more organs were affected. Histologically the
tissue samples were then assigned to stage 3 or 4. At the level of
Southern blot analysis no differences among animals with mild or
severe lesions were detected with respect to the integrated transgene.
Identification and characterization of the disrupted host sequences
are needed to understand the complex mechanisms underlying the
development of these lesions.
This paper describes the development of heritable melanomas in
transgenic mice made with a DNA fragment that is not a known
oncogene. Our results suggest that the site of integration of the
transgene plays a vital role in the development of the tumors. The
availability of these transgenic animals affords an excellent model system
with which to investigate the host gene(s) that are involved in the
development of melanoma.
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Figure 4. Electron micrograph from stage 2 lesion. Multiple membrane-
bound melanosomes and premelanosomes are present within the cytoplasm.
With progression of the lesion, neoplastic cells became filled with melanosomes,
which displace and obscure other organelles. Scale bar, 5 µm.
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